CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy
Behrouz Shademan, Vahidreza Karamad, Alireza Nourazarian and 1 more
Advanced Pharmaceutical Bulletin · 2022
doi:10.34172/apb.2022.051 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Immunotherapy has become a prominent strategy for the treatment of cancer. A method thatimproves the immune system’s ability to attack a tumor (Enhances antigen binding). Targetedkilling of malignant cells by adoptive transfer of chimeric antigen receptor (CAR) T cells is apromising immunotherapy technique in the treatment of cancers. For this purpose, the patient’simmune cells, with genetic engineering aid, are loaded with chimeric receptors that haveparticular antigen binding and activate cytotoxic T lymphocytes. That increases the effectivenessof immune cells and destroying cancer cells. This review discusses the basic structure andfunction of CAR-T cells and how antigenic targets are identified to treat different cancers andaddress the disadvantages of this treatment for cancer.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.